Immune surveillance against tumors usually depends on T cell recognition of tumor antigens presented by major histocompatibility complex (MHC) molecules, whereas MHC class I tumors may be controlled by natural killer (NK) cells. Perforin-dependent cytotoxicity is a major effector function ofCD8 + MHC class I-restricted T cells and of NK cells. Here, we used perforin-deficient C57BL/6 (PKO) mice to study involvement of perforin and Fas ligand in tumor surveillance in vivo.
T umor cells arise in individuals as a result of exposure to rnutagenic chemicals, radiation, viruses, or spontaneous mutations (1) . Whether or not an individual succumbs to the tumor depends on the balance between growth kinetics and metastatic capacity of the tumor versus the ability of the host to control the tumor. For this, the host has two major mechanisms at its disposal: innate and acqmred immunity. Innate immunity (e.g., NK cells) is not antigen specific and is able to act quickly and without priming. Acquired immunity depends on primxng, is therefore relatlvely slow but highly specific, and has a memory. A tumor can prime acquired immunity if it presents tumor-specific antigens in the context of MHC class I or class II molecules to CD8 + or CD4 + T cells, respectively (1) (2) (3) . Furthermore, expression of costimulatory molecules (e.g., B7, intracellular adhesion molecule-I, and LFA-3) has been shown to dramatically increase the efficiency of prinung in certain instances (4) (5) (6) (7) . Under selective pressure, however, tumor escape variants that lack MHC class I or II molecules, costimulatory molecules, or tumor-specific antigens (8) (9) (10) (11) may arise. Some escape variants that had lost MHC class I expression are efficiently controlled in vivo by NK cells (12, 13) in a strictly perforin-dependent way (13) .
Perforin-deficient (PKO) 1 mice have been generated on a C57BL/6 genetic background (H-2 b) by homologous recombination and are healthy under specific pathogenfree conditions (14) . PKO mice completely lack perforindependent cytotoxicity, whereas the Fas (CD95)/FasLigand (FasL)--dependent cytotoxic pathway is unimpaired (14) (15) (16) (17) (18) (19) (20) (21) (22) . Therefore, PKO mice allow the assessment of the relative contribution of each of the two major cell-mediated cytotoxic pathways to a variety of immune responses in vivo and in vitro (14, 15, (17) (18) (19) (20) (21) (22) . We have shown previously that the defense against infection with the noncytopathic lymphocytic choriomeningitis virus (LCMV) or, to a lesser extent, with the intracellular bacterium Listeria monocytogenes depends on perforin-dependent cytotoxicity (14, 17, 23) .
Control of syngeneic MC57G fibrosarcoma cells was 10-fold better in C57BL/6 mice compared to PKO mice (14) . Also, the development ofinsuhn-dependent diabetes mellitus in a transgenic model (24) is perforln dependent. On the other hand, PKO mice were normal with respect to control of infection with cytopathic viruses like vaccinia virus (VV) or Semliki forest virus (25) . Finally, a role for perforin-dependent cytotoxicity was demonstrated in rejection of MHC class 1-disparate allografts such as heart (26) and allogeneic tumor cell lines (27) , as well as in mixed lymphocyte reactions in vitro (14, 15) , and in GVHD (28) .
Here, we evaluate the role of perforin-and Fas-dependent cytotoxicity in the control of a variety of established, transplantable syngeneic MHC class I + tumor cells in vivo and assess the susceptibility of PKO mice to primary individually arising tumors induced by chemical carcinogens and by an oncogenlc virus.
thracene-induced T lymphoma (American Type Culture Collection [ATCC], Rockville, MD). B16 is a spontaneous melanoma, MC57G is a methylcholanthrene-induced fibrosarcoma (31) , and MBL-2 is Moloney virus-reduced lymphoma. N1 are EL-4 cells stably transfected with the nucleoprotein (NP) of vesicular stomatitis virus (VSV), and V1 is a mock-transfected control (N1 and V1 were originally obtained from L. Lefrancois, Division of Rheumatology, Connecticut Health Center, Farmington, CT; 32). SR23B adenovirus type 5 early region I (Ad5EI) + EJras transformed tumor cell line was generated from mouse embryonic cells as described previously (33) and contains an Ad5E1B-encoded CTL epltope. All cell lines were of C57BL/6 origin and were maintained in IMDM supplemented with 5% FCS and antibiotics.
Monoclonal rat anti-mouse CD4 (YTS191.1) and monoclonal rat anti-mouse CD8 (YTS169.4) were originally obtained from Dr. H. Waldmann (Dunn School of Pathology, Oxford, UK; 34). Treatment involved injection of 2 mg l.p. of the appropriate antibody. Efficiency of depletion was checked by FACS ® analysis (Becton Dickinson & Co.). Purified monoclonal hamster antimouse TNF-0~ TN3-19.12 has been described (35) and was kindly provided by Dr. R. Schrelber (Washington School of Medicine, St. Louis, MO); TN3-19.12 was used in vivo at 0.25 mg/wk (two injections maximal) to neutralize TNF-ot.
VSV Indiana (Mudd-Summer isolate) was originally obtained from Dr. D. Kolakofsky (University of Geneva, Geneva, Switzerland) and were grown on BHK21 (baby hamster kidney, ATCC CRL 8544) cells infected with low multiplicity of infection (moi) and plaqued on Veto cells. VV expressing the NP of VSV (VV-VSV-NP) was kindly given by Dr. B. Moss (National Institutes of Health, Bethesda, MD; 36). VV expressing FasL has been described (37) . All VV stocks were made on BSC40 cells. LCMV, isolate WE (LCMV-WE), was initially obtained from Dr. F. Lehmann-Grube (Heinnch-Pette Institfit fiir Experimental Virologie und Immunologle, Universlt~it Hamburg, Germany; 38) and was propagated in L929 fibroblast cells. Moloney murlne sarcoma and leukemia virus (MoMSV) complex was prepared and tltered as described previously (39) .
Materials and Methods

Mice
Inbred C57BL/6 mice were obtained from the Institute ffir Zuchthygiene (University of Zi.irich, Switzerland). PKO (14) , CD8-deficient mice (CD8-/-; 29), and RAG-2-deficient mice (1LAG2-/-; 30) have been described before and were bred under specific pathogen-free conditions in our own facilities. PKO mice had a C57BL/6 (H-2 b) background. Mice at least 7 wk old were used in all experiments that were performed according to cantonal and federal laws on animal protection, which requires use of minimal numbers of experimental animals.
Cell Lines, Antibodies, attd Viruses
RMA is a mutagenized RBL-5 (Kauscher virus-reduced T lymphoma [12] ) cell line. EL-4 is a 9,10-dimethyl-l,2-benzanIAbbrewatlons used in this paper: DMBA, 7, 
Transfection of Cell Lines with Fas
MBL-2 cells were stably transfected with a construct carrying the mouse Fas gene and the neomycin resistance gene (kindly provided by Dr. P. Golstein, Centre d'Immunologle INSERM-CNRS, Marseille, France; 22) by electroporation and were subsequently selected with 0.9 mg/ml geneticm (G418; Glbco BRL, Basel, Switzerland). G418-resistant cells were checked for Fas expression by FACS ® analysis: 1 million cells were incubated with 10% normal hamster serum (15 rain at 4°C) followed by biotinlabeled hamster anti-mouse Fas (Jo-2: PharMlngen, San Diego, CA) mAb. Cells were stained with streptavldin-FITC or streptavldin-PE. Fas + cell lines were subcloned by limiting diluuon. MBL-2 and MBL-2.Fas cells were insensitive to TNF-mediated cytotoxiclty in vitro (data not shown).
Fas-dependent Cytotoxicity Assay
To test whether the transfected Fas was funcuonal, Fas-transfected (Fas ÷) and control (Fas) cell lines were labeled with Na51CrO4 and were used as targets for FasL + effectors. FasL + effectors were generated by infecting MC57G fibroblasts with VVFasL (37) for 2 h with a multiplicity ofinfectin (moi) of 2. Effectors and targets (104 per well) were incubated for 5 h at 37°C in a standard 51Cr release assay. In addition, PKO and control 
Tumor Induction In Vivo by Injection of Tumor Cell Lines
Normal Untreated Mice. PKO and C57BL/6 mice were injected intraperitoneally with different amounts of viable tumor cells (Table 1 ). Mice were monitored daily for tumor growth by determining their weight; they were killed if the weight increased to more than 15% compared to noninjected controls. In case of S1K23B cells, subcutaneous tumor volume was deterrmned with a caliper measuring two perpendicular diameters. 
Effect of Priming with Viral
Tumor Induction by Tumorigenic Agents
Carcinogenic Chemicals. Groups of 10 C57BL/6, PKO, and CD8 -/ mice were rejected subcutaneously in the left hind leg with 0.1 ml corn oil containing 25, 100, or 400 btg methylcholanthrene (MCA), and mice were monitored weekly for fibrosarcoma development.
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Alternatively, 100 ~1 acetone containing 10 nmol 12-O-tetradecanoyl-phorbol-13-acetate (TPA) and 3 nmol 7,12-dlmethylbenzanthracene (DMBA) was applied twice weekly on the shaved skin of the back to groups of eight C57BL/6 and PKO mice. Skin application was continued during the course of the experiment, and mice were observed twice per week for the development of papillomas (41).
MoMSV. Groups of 5-10 C57BL/6 and PKO (untreated, anti-TNF-treated, CD4-or CD8-depleted) or CD8 /-mace were injected m the left thigh with 100 ILl PBS i.m. containing 103 focus forming units of MoMSV complex, as has been described (39) . Mice were monitored for tumor growth, and tumor size was determined using a caliper measuring two perpendicular diameters.
Isolation and Culture of MCA-induced Sarcomas
When MCA-mduced sarcomas had reached a volume of ~0.5 cm 3, mice were killed and tumors were removed asepucally. Tumors were cut into small pieces and were trypsmlzed for 5 h at room temperature, clumps were removed, and single cells were cultured in IMDM supplemented with 10% FCS, glutamme, and antibiotics. Cells were split when they reached confluency. All sarcomas could be kept in culture for at least 3 too. The expression of MHC class I, class II, and Fas was determined by FACS ® analysis.
Statistical Analysis
Results were compared statistically using the unpaired MannWhitney U test.
Results
Petforin Plays a Role in Surveillance against Most Established Tumor Cell Lines
PKO mice and C57BL/6 mice were rejected with syngeneic tumor cell lines of different tissue origins, and tumor growth was monitored.
Tumors of Nonlymphoid Origin. B16 melanoma cells grew unrestricted in both C57BL/6 and PKO mice, even when The cell numbers in the table represent the lowest number of tumor cells that could not be controlled in vlvo. The numbers in brackets are the number of mice with tumors out of the total number tested which were obtained In two to three independent experiments with groups of two to three rmce. *Mice were primed with tumor cells (MBL-2, P, MA) by injection of 5 X 106 irradiated tumor cells (MBL-2, MBL-2 Fas, P, MA) at days -14 and -7 before tumor challenge at day 0 or with viral anugens (VSV, VV-VSV-NP) by ln lecnon of 2 × 106 PFU at day -14 betbre tumor (VSV-NP-transfected or mock-transfected EL-4) challenge at day 0.
as little as 100 cells were injected. MC57G fibrosarcoma cells were controlled 10-fold better by C57BL/6 mice than by PKO mice (Table 2 ) (14). In contrast, 107 adenovirus + ras-tranformed mouse embryonic cells (SR23B) were rejected by both unprimed mouse strains (Fig. 1) . The tumors were smaller in PKO mice, suggesting even a better control by these mice. After priming with irradiated SR23B cells, both mouse strains were equally protected against tumor growth (data not shown).
Tumors of Lymphoid Origin. EL-4 and MBL-2 cells were
controlled 100-1,000-fold better by naive C57BL/6 mice when compared to naive PKO mice (Table 2 and Fig. 4 ). Priming with tumor cells (MBL-2) even increased the resistance against subsequent challenge 100-fold in C57BL/6 and PKO mice ( Table 2) . As previously shown (42), EL-4 tumor cells expressing a wral antigen derived from VSV (N1), but not their mock-transfected counterparts (V1) were readily controlled by mice that had been previously primed with the virus (Fig. 2) . In PKO mice, however, both N1 and V1 showed uncontrolled growth, indicating that this form of antitumor immunity ~s essentially mediated by perforin. P, MA cells, which are related to MBL-2 cells, however, were controlled to a similar extent in both naive and primed C57BL/6 and PKO mice. The MHC class I-derivative of RMA cells, P,.MA-S (12), was controlled considerably better by C57BL/6 mice (13). The data shown in Table 2 were obtained using two to three mice per group in two to three independent experiments in which established tumor cell lines were "titrated" into mice with 10-fold differences in cell number injected. was the case in 100% of the mice tested and, in addition, a 10-fold lower load of the same tumor cell line was always controlled. An exception to this was formed by MBL-2.Fas cells in primed PKO mice: in both experiments, one out of two mice controlled 10 ° cells, and one out of two controlled 10 s cells, but died after 106 cells, albeit with a delay of 2 wk compared to the time mice usually died in these experiments (Fig. 4) .
Stable Transfection of MBL-2 Lymphoma Cells with Functional Fas
MBL-2 cells were transfected with an expression vector encoding mouse Fas and G418 resistance by electroporation, and G418-resistant MBL-2 cells were subcloned twice. One of the selected subclones (MBL-2.Fas9) displayed a homogeneous expression pattern of Fas (Fig. 3 A) and was killed by FasL + MC57G cells (Fig. 3 B) . Spleno-
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Me-"~-- (Fig. 3 C) . As expected, untransfected MBL-2 cells (virtually Fas-, Fig. 3 A) were killed by C57BL/6 effectors, but only to a low extent b~¢ perforin-deficient effectors (14) ; this suggested a major role for the perforin-dependent cytolytic pathway against Fas-or Fas l°w targets. Thus, transfection of MBL-2 cells with Fas generated a cell line with a high, stable, and functional expression of Fas.
We also transfected MC57G and B16 cells with Fas and obtained clones with high expression. In vitro, however, these cells remained insensitive to Fas/FasL-mediated apoptosis (data not shown), probably because of a lack of crucial intracellular signalling molecules downstream of Fas (43) . Therefore, no in vivo experiments were performed with MC57G.Fas and B16.Fas cells.
Resistance against Fas-transfected MBL-2 Cells
To evaluate whether growth characteristics of MBL-2 cells were influenced by Fas, MBL-2 and MBL-2.Fas cells were titrated intraperitoneally in RAG2 -/-mice. In addition, growth kinetics in vitro were compared. We did not observe differences in tumor take or tumor growth between MBL-2 and MBL-2.Fas cells at the doses tested (102-104-106, RAG2 /-mice could not control the tumor) in RAG2 -/ mice or of proliferation in vitro (data not shown). The potency of Fas/FasL interactions in tumor surveillance in vivo was investigated in naive or primed mice. Naive C57BL/6 mice controlled 103 MBL-2 cells and 104 MBL-2.Fas cells, but could not control an inoculum of 104 MBL-2 or 105 MBL-2.Fas. As little as 102 MBL-2 cells grew in an uncontrolled fashion in PKO mice, whereas 102 MBL-2.Fas cells were rejected (Fig. 4) . This suggests that in an unprimed situation, Fas/FasL interactions may contribute to tumor control.
In a subsequent experiment, mice were primed intraperitoneally with 4 million irradiated MBL-2 cells. Mice were subsequently challenged with different numbers of viable MBL-2 or MBL-2. Differences between PKO and C57BL/6 rmce were statistically significant (unpaired Mann-Whitney U test), whereas differences between CD8 -j-and C57BL/6 mice were not against a >104-and a >103-fold higher dose of MBL-2 in C57BL/6 and PKO mice, respectively. In C57BL/6 a >103-fold and in PKO an 103-fold higher protection was induced against MBL-2.Fas.
Tumors hzduced by Chemical Carcinogens
Subcutaneous injection of MCA induced fibrosarcomas in a dose-dependent fashion. Injection of 25 bLg (Fig. 5, top) induced tumors in 100% of the PKO, but only in 20% of the C57BL/6 mice. Administration of 100 Ixg MCA mice induced sarcomas with comparable kinetics and incidence as those seen in C57BL/6 mice. Experimental groups were statistically compared using the unpaired MannWhitney U test, and showed that tumor development In PKO mice and C57BL/6 mice was statistically different after injection of 100 Ixg MCA (P <0.0005) or 400 I.Lg MCA (P <0.009). The difference between PKO and CD8 -/-mice was also statistically significant (P <0.0008), whereas there was no difference between C57BL/6 and CD8 -/ mice (P = 0.9). Statistical analysis was not performed on groups injected with 25 I~g MCA, because only one out of five C57BL/6 mice, but five out of five PKO mice, developed a sarcoma. FACS ® analysis performed within 10 d after isolation of different MCA-lnduced sarcomas showed that the sarcomas were MHC class I I°w/-, MHC class II-, and Fas-(not shown). The expression of the above-mentioned surface molecules was similar in the three different strains of donor mice.
The first DMBA+TPA-induced skin papillomas developed in C57BL/6 and PKO mice after 18 wk and 21 wk, respectively, and 100% incidence was reached after 31.5 and 34 wk, respecnvely (Fig. 6) . The incidence and kinetics of DMBA+TPA-induced papillomas were similar in PKO and C57BL/6 mice, arguing against a role for perforin-mediated cytotoxicity (CTL and/or NK) in the control of DMBA+TPA-induced papillomas.
Virally Induced Fibrosarcomas
Intramuscular administration of MoMSV to PKO and C57BL/6 mice led to tumor induction in all mice with similar kinetics. In addition, occurrence of regression was not dependent on perforin (Fig. 7) . Nevertheless, the tumors were larger on average and regression was retarded in PKO mice, suggesting involvement ofperforin in the acute effector phase of tumor rejection. CD8-depleted C57BL/6 mice displayed similar tumor size and regression kinetics as PKO mice (not shown), indicating that CD8 ÷ T cells, and not NK cells, exert the perforin-mediated effect. CD4-depleted C57BL/6 mice, on the other hand, developed large tumors that could not be eliminated (data not shown). We observed that PKO and C57BL/6 mice were sick and lost weight when the tumor reached its peak size. Treatment with anti-TNF-(x antibody abolished this sickness. Tumor size and kinetics of regression, however, were not affected by this treatment.
Discussion
The perforin dependence of the eradication of several established syngeneic tumor cell lines was investigated. Most cell lines showed a difference in tumorigenic dose between naive PKO and C57BL/6 mice, indicating that even without previous priming, perforin-mediated cytotoxicity is a crucial effector mechanism in tumor control. In primed mice, the difference between PKO and wild-type mice was even more clear. This suggests that priming of CD8 + CTLs 1787 van den Broek et al.
rather than priming ofCD4 + T cells is responsible for resistance to high tumor loads in C57BL/6 mice. Two tumor cell lines formed an exception to this rule. RMA cells showed equal growth in both naive (104) and primed (10 6) PKO and C57BL/6 mice, which may be explained by the fact that control is mediated by perforinindependent mechanisms, probably by CD4 ÷ cells using an unidentified effector mechanism (1). Because RMA and MBL-2 are related lymphoma lines and express similarly high levels of MHC class I and no MHC class II, and both cell lines are Fas l°w, the observation that the control of RMA is not dependent on perforin, whereas the control of MBL-2 cells is, was unexpected. This may be explained by a difference in efficiency of priming CD4 + and/or CD8 + T cells, or by a different growth rate of RMA vs. MBL-2 cells. The second exception is formed by SR23B cells: this adenovirus + ras-transformed cell line induced larger tumors in C57BL/6 mice than in PKO mice. This unexpected finding may be explained by the fact that PKO mice may have increased basal levels of macrophage activation and/or cytokines such as interferon-',/and TNF-oe as compensatory mechanisms, all of which are known to possess antitumor activity.
Stable transfection of MBL-2 cells with Fas rendered them susceptible to Fas/FasL-dependent apoptosis in vitro. To investigate the contribution of the Fas pathway to in vivo tumor surveillance, control of MBL-2.Fas and MBL-2 cells was compared in naive and primed PKO and C57BL/6 mace. In unprimed PKO and C57BL/6 mice, Fas + cells were controlled 10-fold better compared to Fas-cells. Priming of PKO mice increased the number of tumor cells needed for uncontrolled growth by 100-fold for both MBL-2 (10 4 cells) and for MBL-2.Fas (10 s cells), suggesting priming of perforin-independent mechanisms. Priming of C57BL/6 mice, however, resulted in control of >106 MBL-2 or MBL-2.Fas cells, stressing the need for a collaboration between perforin-dependent and -independent mechanisms for full immune protection against MBL-2 cells. Thus, our experiments failed to detect a major involvement of Fasdependent cytotoxicity in tumor control, but cannot exclude a minor role.
To investigate the influence of perforin on the induction of primary tumors in vivo, we analyzed different models in which tumors are induced by chemicals (MCA, DMBA+TPA) or virus (MoMSV). The major difference of this approach compared to injection of syngeneic cell lines is that the immune system is not confronted with a considerable tumor load at once, but that immunosurveillance is tested at the very moment a tumor arises. Moreover, in contrast to injection of homogeneous cell lines, each mouse develops its own tumor that may have individually different tumor antigens, even if the same chemical is injected in the same animal (44) . Subcutaneous injection of MCA is known to induce sarcomas at the site of injection (44) that usually do not regress once they developed. C57BL/6 and CD8 / mice developed sarcomas with a high incidence but with much slower kinetics than PKO mice. This suggests that NK cells or CD4 + T cells may act directly or indirectly as important effectors controlling MCA-induced sarcomas. Ex vivo analysis of MHC class I, class II, and Fas expression of MCA-induced sarcomas, however, showed that sarcomas were Fas and MHC class II-and were MHC class I -/l°w, independent of whether they were isolated from PKO, C57BL/6, or CD8 / mice. Although MHC class I expression could be upregulated to high levels by exposure to IFN-',/ in vitro (not shown), it remains unclear whether this occurs in vivo. Because four out of four MCA-induced sarcomas tested were sensitive to NK-mediated lysis in vitro, this suggests that NK-mediated control may be an important pathway in vivo. In a second set of experiments in which DMBA+TPA-induced skin papillomas were studied, no differences in incidence, kinetics, or size of papillomas were observed between PKO and C57BL/6 mice, indicating that perforin does not play a key role. Because the latter model is immunologically not characterized (susceptibility of SCID or nu/nu mice is not known), it ~s not possible at the present time to be more specific about possible effector mechanisms.
Sarcomas induced by inoculation of mice with MoMSV are known to be rejected within 3 wk by immunocompetent mice in which a prominent H-2Db-restricted CTL response is observed (45) (46) (47) (48) , whereas lethal tumors develop in nu/nu mice (Ossendorp, F., and C.J.M. Melief, unpublished data). Furthermore, CD4 depletion results in uncontrolled tumor growth (Ossendorp, F., and C.J.M. Melief, unpublished data). CD8 depletion, on the other hand, did not alter the incidence or kinetics of tumor growth, but led to a significant delay in tumor rejection (data not shown). PKO mice &splayed a phenotype similar to CDS-depleted mice after inoculation w~th MoMSV, suggesting a distinct, perforin-dependent role for CD8 + CTLs in tumor control, although the tumor could be rejected without this pathway. It is not known at the present time which effector mechanism is used by CD4 + T cells to reject MoMSVinduced sarcomas, and this question is subject to further stu&es. Apparently, CD4 + T cells do not eradicate tumors through TNF-ot because treatment with neutralizing anti-TNF antibodies in vivo improved the general well-being of the mice at the peak of the tumor growth, but did not interfere with tumor rejection (data not shown) independent of mouse strain or treatment.
Finally, during the 3 yr we now have bred PKO mice and have kept some ("-'100) for >12 mo, we have not observed spontaneous tumors of any kind. This does not necessarily call into question the in vivo relevance of perforin for tumor control because (a) a mouse facility is a relatively protected environment in which mice are not exposed to irradiation, toxins, chemicals, or exogenous oncogenic viruses; and (b) spontaneous tumor development may be too rare for meaningful observation in the few mice that were not used for experiments when young and reached an age of >1 yr in our facilities.
Taken together, our data illustrate that several mechanisms may control tumor growth; perforin-mediated cytotoxicity by CD8 ÷ CTLs (for MHC class I ÷ tumors) and NK cells (for tumors expressing low levels of MHC class I) are of major importance; Fas/FasL interactions can contribute to tumor control in vivo, albeit to a lesser extent than perforin-dependent lysis, at least in tumor models using several established tumor cell lines or primarily induced types of tumors studied here.
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